The G protein-coupled receptor family, which includes the glucagon receptor (GCGR), is crucial for regulating blood sugar levels. The class B G-protein coupled family of receptors includes the glucagon receptor, a 62 kDa protein that is activated by glucagon and coupled to G alpha i, Gs, and to a lesser extent G alpha q. Adenylate cyclase is activated and intracellular cAMP levels are raised when the receptor is stimulated. The GCGR gene in humans is responsible for encoding the glucagon receptor. The liver and kidneys are the primary sites of glucagon receptor expression, with smaller amounts of these receptors also present in the heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V81355 | SAR441255 | SAR441255 is a potent single-molecule peptide GLP-1/GIP/GCG receptor agonist. | |
|
V76524 | Secretin (33-59), rat TFA (Secretin (rat) (TFA)) | Secretin (33-59), rat (TFA) is a polypeptide consisting of 27 amino acid (AA)s, which can act on the secretin receptor and enhance the secretion of carbonate, enzymes and potassium ions in the pancreas. | |
|
V4644 | Semaglutide | 910463-68-2 | Semaglutide (NNC 0113-0217; NNC-0113-0217; Ozempic) is a novel and potent agonist of glucagon-like peptide-1 (GLP-1) receptor and belongs to the long-acting GLP-1 analogue. |
|
V27892 | Semaglutide acetate | 1997361-85-9 | Semaglutide acetate (NNC-0113-0217; NNC0113-0217), the acetic acid salt form of semaglutide (Ozempic), is a human glucagon-like peptide-1 (GLP-1) receptor agonist with longer duration of antidiabeticaction. |
|
V3909 | SEMAGLUTIDE TFA | Semaglutide TFA (NNC0113-0217; NNC-0113-0217), the trifluoroacetic acid salt form of semaglutide (brand name: Ozempic), is a human glucagon-like peptide-1 (GLP-1) analogue acting as a GLP-1 receptor agonist with longer duration of antidiabetic action. | |
|
V4234 | tirzepatide | 2023788-19-2 | Tirzepatide (formerly known as LY3298176; trade name Mounjaro) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved by FDA in May 2022 for the treatment of type 2 diabetes. |
|
V74582 | TT-OAD2 free base | 1246826-07-2 | TT-OAD2 free base is a non-peptide glucagon-like peptide 1 (GLP-1) receptor agonist/activator with EC50 of 5 nM. |
|
V51121 | Utreglutide | 2460862-12-6 | Utreglutide is a potent glucagon-like peptide 1 (GLP-1) receptor agonist (activator). |
|
V74571 | Volagidemab (REMD-477; AMG-477) | 1233956-13-2 | Volagidemab is an antagonist glucagon receptor (GCGR) monoclonal antibody (mAb). |
|
V28095 | VU0453379 | 1638646-27-1 | VU0453379 (VU-0453379; VU 0453379) is a novel, CNS-penetrant and potent glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM) with EC50 of 1.3 μM. |
|
V76350 | VU0453379 hydrochloride | VU0453379 HCl is a selective and central nervous system/CNS permeable (penetrable) PAM (positive allosteric modulator) of the glucagon-like peptide receptor (GLP-1R) with EC50 of 1.3 μM. | |
|
V77336 | {Val1}-Exendin-3/4 | {Val1}-Exendin-3/4 is residues 1-28 of the N-terminus of the Exendin-4 polypeptide. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
